(Sept 25): Erica Ollmann Saphire spent the past year and a half profiling the coronavirus, creating intricate three-dimensional images in her San Diego lab to understand its most problematic features. That information is now revealing the pathogen’s weak spots and ways to exploit them. “We now have a framework for selecting durable antibody cocktails for Covid-19 treatment,” said Ollmann Saphire, who is president and chief executive officer at the La Jolla Institute. One “rock star” antibody developed by a collaborating lab is so far outperforming more than 350 other candidates analyzed by the Coronavirus Immunotherapy Consortium that Ollmann Saphire is leading. “It’s fantastic,” Ollmann Saphire said.
